4 completed, 3 active not recruiting, 1 suspended. 7 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Active not recruiting 3, Completed 3, Suspended 1 |
| Phase 2 | 5 | Completed 4, Active not recruiting 1 |
Follow pepinemab: new trials by email Literature Review of pepinemab trials Research Report on pepinemab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma Avelumab and Pepinemab - Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Vaccinex Inc. | 48 | 2022-12-10 | 2025-05-21 |
| Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer Dendritic Cell (DC1) Vaccine, Trastuzumab, Pepinemab - HER2-positive Breast Cancer | Phase 1 | Suspended | H. Lee Moffitt Cancer Center and Research Institute | 28 | 2022-05-31 | 2026-09-15 |
| Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck pepinemab + pembrolizumab - Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) | Phase 1 / Phase 2 | Completed | Vaccinex Inc. | 49 | 2021-08-09 | 2025-01-08 |
| SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD) Pepinemab, Placebo - Alzheimer Disease | Phase 1 / Phase 2 | Completed | Vaccinex Inc. | 50 | 2021-07-22 | 2024-08-22 |
| VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma Ipilimumab, Nivolumab, VX15/2503 - Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Phase 1 | Active not recruiting | Emory University | 41 | 2018-12-13 | 2026-05-05 |
| VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer VX15/2503, Ipilimumab, Nivolumab - Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Active not recruiting | Emory University | 35 | 2018-11-01 | 2026-07-16 |
| Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Laboratory Biomarker Analysis, Pepinemab, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 26 | 2018-01-31 | 2024-07-15 |
| A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi VX15/2503, Placebo - Huntington's Disease | Phase 2 | Completed | Vaccinex Inc. | 301 | 2015-07-01 | 2022-05-02 |
Squamous Cell Carcinoma of Head and Neck (2) · Alzheimer Disease (1) · Breast Neoplasms (1) · Carcinoma (1) · Cognitive Dysfunction (1) · Huntington Disease (1) · Neoplasm Metastasis (1) · Osteosarcoma (1) · Prodromal Symptoms (1) · Recurrence (1)
Vaccinex Inc. (4) · Emory University (2) · Children's Oncology Group (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
United States (8) · Canada (1)
Andrew Feigin, MD (1) · Conor Steuer, MD (1) · Daniel Mulkerin, MD (1) · Emily G Greengard (1) · Eric Siemers, MD (1) · Heather Han, MD (1) · Michael Lowe, MD, MA (1)
PMID 30103342, PMID 31401903, PMID 35941373, PMID 36463457, PMID 38520670
P30CA138292 (1), UM1CA097452 (1)